In fact, recent studies on lung cancer cell lines demonstrated that the level of BCL-XL expression could be a key mechanism in controlling the resistance to cell death induced by PI3K/AKT inhibition [26]. The gene discussed is BCL2L1; the disease is lung carcinoma.